Q-line Biotec Summary
The Q-Line Biotech Ltd can be classified under the biotechnology / in vitro diagnostics (IVD) industry, and in its business operations, the company deals with the market of healthcare diagnostics and medical devices. This company is engaged in the development, manufacture, marketing and distribution of reagents (kits and point-of-care or POC devices), consumables, diagnostic devices, and pathology devices to meet different healthcare diagnostic requirements. Manufacturing of reagents of clinical chemistry, haematology, immunodiagnosis, molecular diagnosis, and other rapid test devices (POC devices & rapid tests) is an important part of its business, along with the importation and supply of diagnostic equipment.
In its business operations, the company adopts a B2B (business-to-business) strategy that focuses primarily on hospitals, diagnostic labs, medical colleges, and pathology services providers in India. Products offered by the company include branded IVD reagents, kits and devices, providing customers with indigenous and cost-effective products as opposed to totally depending on imported products. In addition to assay systems, the company also provides POC diagnostic devices and rapid test formats, making it possible for healthcare providers to conduct tests quickly at the point of care.
Q-Line Biotech Ltd plans to make an NSE SME IPO of equity shares with a face value of ₹10 each at a price band of ₹326–₹343 per share, on a book‑built SME IPO route through NSE SME. The total issue size is ₹214.48 crore, comprising a fresh issue of approximately ₹203.74 crore and ₹10.74 crore reserved for the market maker. The IPO is structured with QIB (including anchor investors), NII (HNI), and Retail investor categories, with the majority of the net offer allocated to QIBs and Retail, as per the reservation pattern disclosed in the offer document.
Q-line Biotec IPO Details:
Q-line Biotec Limited Issue Management:
Hem Securities Ltd. acts as the book-running lead manager for Q-line Biotec NSE SME IPO, managing underwriting and compliance.
Q-line Biotec Limited IPO RTA (Registrar) Details:
Purva Sharegistry (India) Pvt.Ltd. handles allotment, refunds, and demat credits - contact at +91-022-23018261/ 23016761 or support@purvashare.com.
Q-line Biotec Limited IPO Allotment Status:
To check your IPO allotment status:
Visit the Purva Sharegistry (India) Pvt.Ltd. IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Q‑Line Biotec Ltd. SME IPO totals ₹214.48 Cr, comprising a fresh issue of ₹203.74 Cr and ₹10.74 Cr reserved for the market maker. The face value is ₹10 per share and the price band is ₹326–₹343 per share (book‑built issue on NSE SME).
Q-line Biotec Limited IPO proceeds from the fresh issue will be deployed towards:
Q‑Line Biotec IPO offers 62,53,200 equity shares (total issue ₹214.48 Cr), with 59,40,000 as net offer to the public and 3,13,200 reserved for the market maker.
The anchor bidding for Q‑Line Biotec Ltd. SME IPO is scheduled for 20th May 2026, one working day before the issue opens on 21st May 2026, and anchor investors will be allotted shares from the QIB portion (within the overall QIB tranch, as per SME IPO structure). As per the IPO reservation details, the QIB portion (including anchor) accounts for about 49.99% of the net issue size, with the remainder allocated to NII (15.01%) and Retail (35.00%).
Lock-in: The anchor allocation follows standard SME IPO norms, where 50% of the anchor shares are locked in for 30 days and the remaining 50% for 90 days from the listing date. The issue is scheduled to list on 29th May 2026 on NSE SME.
The anchor allocation details and investor list will be disclosed in the anchor book before the IPO opening. Hem Securities Ltd. is the Book Running Lead Manager (BRLM) to the issue, and the registrar for the IPO is Purva Sharegistry (India) Pvt. Ltd.
The profitability of Q-Line Biotec Ltd is mainly due to its business model, which has been concentrated in the biotechnology and IVD industry, whereby the firm designs, manufactures and markets various types of reagents, kits, POC devices and consumables as well as supplying and distributing diagnostic equipment. The company makes money through its B2B business to customers such as diagnostic laboratories, hospitals and medical colleges in India, owing to its robust manufacturing capabilities, research and development/reverse engineering capability as well as a national distribution network. The company’s focus on quality control, indigenous manufacturing and product diversification in clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and POC devices contributes to its relatively stable margins.
In terms of finance, the company has performed quite well in terms of growth and profitability: Income has risen from ₹184.81 Cr (FY23) to ₹206.45 Cr (FY24) and ₹322.58 Cr (FY25) at ₹236.50 Cr as on 31 Dec 2025; PAT has jumped from ₹32.10 Cr to ₹34.44 Cr, ₹28.13 Cr and ₹38.69 Cr; while EBITDA has gone up from ₹32.98 Cr to ₹37.63 Cr, ₹71.32 Cr and ₹64.23 Cr, showing operating leverage. PAT margins have been in the mid-teens to high teens level, whereas EBITDA margins have grown from high teens to 27-28%. ROE is estimated at 17-25%; ROCE at mid-20% to low-30% band, very low leverage, and net worth above ₹180–190 Cr as of FY25/Dec 2025.
Action Links:
To apply for Q-line Biotec Limited IPO, open a demat account here
Q-line Biotec Limited IPO Subscription Status: Check live subscription here
Q-line Biotec Limited IPO GMP Update: Check latest grey market premium here
Q-line Biotec Key Highlights:
Q-Line Biotec Ltd. is an organization that belongs to the Biotechnology industry and not to Real Estate related services. The company functions in the field of In vitro Diagnostics (IVD) and Life sciences and is engaged in the production and sale of diagnostic reagents, kits, point of care devices, and consumables as well as the import, manufacture, and sale of diagnostic equipment to healthcare facilities. It caters to diagnostic laboratories, hospitals, and medical colleges of India in a B2B fashion using indigenous manufacturing, research & development, reverse engineering, and pan India distribution channels.
From recent financial statements, Q-Line Biotec Ltd. has demonstrated excellent performance, showing good growth and profitability. Income has been growing from ₹184.81 Cr in FY23 to ₹206.45 Cr in FY24 and ₹322.58 Cr in FY25, with ₹236.50 Cr recorded up to December 2025, implying an increase in size.
Factors contributing to growth include: diversified in-vitro diagnostics and biotechnology business with dependable demand for B2B products in the hospitals, laboratories, and medical colleges in India; competent promoters backed by professional management in diagnostics and R&D industry; increase in working capital to support higher production and distribution of IVD reagents and instruments; and diversification of product lines and geographies to improve asset efficiency and income per project. The R&D driven product development, indigenously manufactured and refurbished & distributed business model helps in scaling up with moderate capital intensity.
Q-line Biotec Risk Factors:
The risks of Q-line Biotec Limited IPO are mentioned below:
High degree of dependence on the healthcare/diagnostics process, associated with hospitals, laboratories, and government-sponsored health expenditure.
Regulatory/quality control risks associated with the biotechnology/IVD business, such as product approval and quality control.
Competition from other large-scale IVD companies, multinational corporations, and local biotechnology firms.
High working capital intensity, with factors like inventory, receivables, and import cycles playing a role.
Low liquidity as an NSE SME-listed firm relative to main-board listed biotechnology companies.
Dependence on R&D-based products; any delays in such products will impact business growth.
Q-line Biotec Expert Analysis:
Q‑Line Biotec Ltd. is launching a book‑built SME IPO on NSE SME with a total issue size of ₹214.48 Cr, comprising a fresh issue of ₹203.74 Cr at a price band of ₹326–₹343 per share (face value ₹10). The issue is structured with 62,53,200 equity shares, of which 59,40,000 are offered to the public (QIB 29,69,200 + NII 8,91,600 + Retail 20,79,200) and 3,13,200 shares reserved for the market maker.
Basic details of the IPO:
Type of IPO: Book‑built SME IPO (NSE SME)
Uses of funds: Funding of capital expenditure – Working capital requirements: ₹93.50 Cr, repayment of certain borrowings: ₹90.00 Cr, general corporate purposes: ₹14.50 Cr
Anchor bidding: Anchor bidding 20 May 2026 | Opens 21 May 2026 | Closes 25 May 2026 | Allotment 26 May | Listing 29 May 2026 (NSE SME).
Lead Manager: Hem Securities Ltd. | Registrar: Purva Sharegistry (India) Pvt. Ltd.
Expert View on the IPO:
The company displays robust top-line growth, healthy PAT margins (in the mid-teens), and excellent ROE/ROCE (in the 20-25% range) with very little leverage and a narrow diagnostics solutions business. The IPO provides investors with an opportunity to participate in the fast-growing Indian diagnostics and IVD industry, although investors should keep in mind that there is regulatory risk, cyclicality in capital expenditure at hospitals and labs, and competition from established players in the sector.
Should you invest in Q-line Biotec?
Investors seeking exposure to biotechnology and IVD diagnostics with a small‑cap, SME‑listed structure may find this IPO worth considering if they are comfortable with sector‑regulatory risk, working‑capital intensity, and modest but improving profitability.
Consider investing when:
You are interested in the exposure of Indian in-vitro diagnostics and biotech growth driven by rising healthcare and laboratory demand.
You are at ease with the liquidity of an SME platform, and the regulatory-R&D-driven nature of the business.
You feel that the company can scale through product diversification, procurement of bigger hospital and laboratory tenders, and market share gain.
Do not invest when:
You have a preference for large-cap and diversified pharmaceuticals/healthcare companies.
You are concerned about regulatory changes, risk of product approval, or slowing of diagnostic and hospital expenditure.
You are apprehensive about NSE SME liquidity and execution risk in R&D/manufacturing expansion.
Investors are advised to exercise discretion and refer to the full DRHP/RHP document before reaching any investment decision. This analysis is for informative purposes and not investment advice.
Action Links:
To apply for Q-line Biotec Limited IPO, open a demat account here
Q-line Biotec Limited IPO Subscription Status: Check live subscription here
Q-line Biotec Limited IPO GMP Update: Check latest grey market premium here
1. What is the Q-line Biotec Limited IPO open and close date?
Q‑Line Biotec Limited IPO opens on 21st May 2026 and closes on 25th May 2026. The anchor bidding is scheduled for 20th May 2026, one working day before the issue opens.
Track Q-line Biotec Limited IPO subscription status live here from Finnpick.
2. What is the Q-line Biotec Limited IPO price band and lot size?
The IPO is a book‑built issue at a price band of ₹326–₹343 per share with a face value of ₹10 per share. The minimum lot size is 400 shares (2 lots for retail = 800 shares, ₹2,74,400 at upper band).
3. What is Q-line Biotec Limited IPO total size?
The total issue size is ₹214.48 Cr (fresh issue of ₹203.74 Cr; 62,53,200 equity shares at ₹343 upper band, including ₹10.74 Cr reserved for the market maker).
4. How to apply for the Q-line Biotec Limited IPO?
Open a demat here (Zerodha/Upstox/AngelOne) or ASBA by May 25, 4 PM. Monitor Q-line Biotec Limited IPO subscription tracker here. Ensure your demat account is active and UPI mandate is approved before the closing time.
5. How to check Q-line Biotec Limited IPO Allotment Status?
The allotment date is on May 26th and can be checked on Purva Sharegistry (India) Pvt. Ltd. RTA portal using PAN/DP ID.
6. What is Q-line Biotec Limited IPO GMP today and subscription status?
Current Grey Market Premium (GMP) stands at ₹63 as of May 19, indicating listing at the price range of ₹406 - check daily updates of Q-line Biotec Limited IPO GMP trends here and live subscription status here from May 21st opening only on Finnpick.
7. What does Q-line Biotec Limited specialize in?
Q‑Line Biotec specializes in developing, manufacturing, and marketing in‑vitro diagnostic (IVD) reagents, kits, POC devices, and consumables, along with the import, manufacturing, and distribution of diagnostic equipment for hospitals, diagnostic labs, and medical colleges.
8. When is the Q-line Biotec Limited IPO listing date?
The Q‑Line Biotec Limited IPO is scheduled to list on NSE SME on 29th May 2026, which is approximately T+3 after the basis of allotment on 26th May 2026.
9. What are the Q-line Biotec Limited IPO proceeds utilization details?
The IPO proceeds will primarily be utilized towards: Working capital requirements (₹93.50 Cr), Repayment of certain borrowings (₹90.00 Cr), and General corporate purposes (₹14.50 Cr, balance).
10. Who are the promoters of Q-line Biotec Limited?
The promoters are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty, and Abhay Agrawal (collective 96.77% pre‑IPO holding, with post‑IPO reduction as per allotment structure).
11. Should I apply for the Q-line Biotec IPO?
Suitable for investors seeking exposure to biotechnology and IVD diagnostics with mid‑teens to high‑teens PAT margins, strong ROE/ROCE, and low debt but with SME‑platform liquidity and sector‑specific regulatory and R&D risk. Watch healthcare‑spending cycle, regulatory changes, and execution in product development. Investors are advised to exercise discretion and refer to the full DRHP/RHP before deciding. This is for informative purposes, not investment advice.
